|
| |
DR. STEVEN A. CURLEY
The Medical News Today article
Cancer Cells Killed By Heating Embedded Nanotubes With Radio
Waves said
US scientists have used non invasive radio waves to heat up carbon
nanotubes embedded in the cancerous livers of rabbits to kill cancer
cells without damaging healthy tissue.
The preclinical study is published in the October 24th early online
issue of the journal Cancer and is the work of Dr Steven A Curley,
professor of surgical oncology at the University of Texas MD Anderson
Cancer Center in Houston, Texas.
Carbon nanotubes are hollow cylinders of pure carbon with a diameter of
one nanometer, or one billionth of a meter.
Curley and colleagues said their method completely destroyed the liver
cancer tumors in rabbits, with no side effects, but there was some heat
damage to neighboring tissue 2 to 5 mm from the tumors. This was due
to nanotube leakage, they said.
"These are promising, even exciting, preclinical results in this liver
cancer model," said Curley, who is senior author of the paper.
Steven A. Curley, M.D., F.A.C.S. is
Professor of Surgery, Chief of Gastrointestinal Tumor Surgery, and
Program Director of Multidisciplinary Gastrointestinal Cancer Care at
M. D. Anderson.
The current focus of his basic science research program is use of a
novel
non-invasive radiofrequency field generator combined with
cell-associated
nanoparticles that release heat in response to the radiofrequency field
to
treat malignant tumors. Ongoing studies involve adding tumor-directed
targeting molecules to the nanoparticles to enhance uptake by malignant
cells while minimizing uptake by normal cells.
Steve earned his medical degree from the University of Texas Medical
School
at Houston. He completed a general surgery residency at the University
of New Mexico Hospitals, and then completed a fellowship in Surgical
Oncology at the University of Texas M. D. Anderson Cancer Center. He
has been on the faculty in the Department of Surgical Oncology
at the University of Texas M. D. Anderson Cancer Center since
completing his fellowship.
His clinical practice and research focuses on surgical and new
treatments for patients with primary or metastatic liver tumors. He has
been a pioneer in designing new treatments for patients with
liver tumors, including radiofrequency ablation, improved techniques
for surgical removal of liver cancers, and several types of direct
tumor injection therapy.
Steve is principal investigator on a number of protocols at
M. D.
Anderson involving radiofrequency ablation of liver tumors or use
of
novel therapies to treat hepatocellular cancer or colorectal cancer
liver metastases. He is also principal investigator on an international
protocol involved in screening high-risk hepatitis virus patients for
hepatocellular cancer and then using surgical therapy, radiofrequency
ablation, or other direct injection treatments to treat patients
diagnosed with small hepatocellular cancers.
Steve is the author or coauthor of over 170 publications, and 60
book chapters, many dealing with the treatment of patients with
hepatocellular cancer, gallbladder cancer, bile duct cancer, or liver
metastases from a number of different tumor types.
He coedited
Gastrointestinal Cancer (M.D. Anderson Cancer Care Series)
and
Radiofrequency Ablation for Cancer: Current Indications,
Techniques and Outcomes,
coauthored
Radiofrequency ablation of unresectable primary and
metastatic hepatic malignancies: results in 123 patients,
Intraoperative radiofrequency ablation or cryoablation for hepatic
malignancies,
Hepatitis B or C virus serology as a prognostic factor in patients
with
hepatocellular carcinoma,
Simplified staging for hepatocellular carcinoma, and
Targeted expression of green fluorescent protein/tumor necrosis
factor-related apoptosis-inducing ligand fusion protein from human
telomerase reverse transcriptase promoter elicits antitumor activity
without toxic effects on primary human
hepatocytes, and authored
Liver Cancer (M.D. Anderson Solid Tumor Oncology
Series).
Print bio!
|
|
